Neisseria meningitidis Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neisseria meningitidis Infections – Pipeline Review, H2 2016’, provides an overview of the Neisseria meningitidis Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria meningitidis Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neisseria meningitidis Infections

The report reviews pipeline therapeutics for Neisseria meningitidis Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neisseria meningitidis Infections therapeutics and enlists all their major and minor projects

The report assesses Neisseria meningitidis Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neisseria meningitidis Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neisseria meningitidis Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Biological E. Limited

China National Pharmaceutical Group Corporation

GlaxoSmithKline Plc

ImmunoBiology Limited

JN-International Medical Corporation

MGB Biopharma Limited

Panacea Biotec Limited

Pfizer Inc.

Sanofi Pasteur SA

Serum Institute of India Limited

Wellstat Vaccines, LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Neisseria meningitidis Infections Overview 10

Therapeutics Development 11

Pipeline Products for Neisseria meningitidis Infections - Overview 11

Pipeline Products for Neisseria meningitidis Infections - Comparative Analysis 12

Neisseria meningitidis Infections - Therapeutics under Development by Companies 13

Neisseria meningitidis Infections - Therapeutics under Investigation by Universities/Institutes 14

Neisseria meningitidis Infections - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Neisseria meningitidis Infections - Products under Development by Companies 18

Neisseria meningitidis Infections - Products under Investigation by Universities/Institutes 20

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development 21

Beijing Minhai Biotechnology Co., Ltd 21

Beijing Tiantan Biological Products Co., Ltd. 22

Biological E. Limited 23

China National Pharmaceutical Group Corporation 24

GlaxoSmithKline Plc 25

ImmunoBiology Limited 26

JN-International Medical Corporation 27

MGB Biopharma Limited 28

Panacea Biotec Limited 29

Pfizer Inc. 30

Sanofi Pasteur SA 31

Serum Institute of India Limited 32

Wellstat Vaccines, LLC 33

Neisseria meningitidis Infections - Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Combination Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

(meningococcal + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

(meningococcal [serotypes A, C, W-135, X, Y] (pentavalent) vaccine - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

MenBioVax - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

meningococcal (tetravalent) vaccine - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

meningococcal [serotype B] vaccine - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

meningococcal [serotype B] vaccine - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

meningococcal [serotype B] vaccine - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

meningococcal [serotype B] vaccine - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

meningococcal [serotype B] vaccine - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

meningococcal [serotype B] vaccine - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

meningococcal [serotype B] vaccine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

meningococcal [serotypes A, B, C, W-135, Y] (pentavalent) vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

meningococcal [serotypes A, C, W, Y] vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

meningococcal [serotypes A, C, W-135, Y] (tetravalent) vaccine 2 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

meningococcal [serotypes A, C, W-135, Y] vaccine - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

meningococcal [serotypes A, C, W135, X, Y] vaccine - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

meningococcal [serotypes A, C, W135] vaccine - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

meningococcal [serotypes A, C] vaccine - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

meningococcal [serotypes C, Y] vaccine - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

meningococcal [strain C2135] vaccine - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

meningococcal vaccine - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

meningococcal vaccine - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

meningococcal vaccine 2 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

MGBBP-3 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Neisseria meningitidis [serotype B] vaccine - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Neisseria meningitidis [serotype B] vaccine - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Nimenrix - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

TP-10 - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Neisseria meningitidis Infections - Dormant Projects 88

Neisseria meningitidis Infections - Discontinued Products 90

Neisseria meningitidis Infections - Product Development Milestones 91

Featured News & Press Releases 91

Sep 05, 2016: ‘Real world’ data shows 83 percent effectiveness for Bexsero in infants in first year of UK national meningitis B immunisation programme 91

May 20, 2016: Pfizer Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For TRUMENBA (Meningococcal Group B Vaccine) 92

May 13, 2016: GSK’s Bexsero achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children 92

May 13, 2016: Pfizer Presents Results From Two Phase 3 TRUMENBA (Meningococcal Group B Vaccine) Studies At The European Society For Paediatric Infectious Diseases Meeting 93

Oct 09, 2015: Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate and Tetanus, Diphtheria and Pertussis Vaccines in Adolescents 95

Aug 21, 2015: Pfizer Announces Positive Topline Results Of Two Phase 3 Studies Of TRUMENBA (Meningococcal Group B Vaccine) 96

Jun 24, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination including TRUMENBA for Adolescents and Young Adults 16 through 23 Years of Age 97

Jun 24, 2015: U.S. CDC committee recommends physicians make individual decisions on the use of meningococcal group B vaccines 97

May 01, 2015: GSK launches first vaccine to prevent meningococcal disease caused by meningococcus B in Brazil 98

Mar 29, 2015: GSK statement on meningitis vaccination in the UK 98

Feb 26, 2015: CDC Advisory Committee on Immunization Practices Votes to Recommend Serogroup B Meningococcal Disease Vaccination for Persons at Increased Risk 99

Feb 24, 2015: Pfizer Announces Positive Top-line Results Of A Phase 2 Study Of TRUMENBA Co-Administered With Routine Meningococcal (A, C, Y, and W) And Tetanus, Diptheria And Pertussis Vaccines In Adolescents 100

Jan 23, 2015: FDA approves a second vaccine to prevent serogroup B meningococcal disease 101

Dec 24, 2014: Cansino Biotechnology: Meningococcal Group ACYW135 Quadrivalent Conjugate Vaccine is Approved for Clinical Trial 102

Nov 18, 2014: TRUMENBA (Meningococcal Group B Vaccine) is Now Available 102

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 103

Disclaimer 104

List of Tables

List of Tables

Number of Products under Development for Neisseria meningitidis Infections, H2 2016 11

Number of Products under Development for Neisseria meningitidis Infections – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Investigation by Universities/Institutes, H2 2016 20

Neisseria meningitidis Infections – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 21

Neisseria meningitidis Infections – Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 22

Neisseria meningitidis Infections – Pipeline by Biological E. Limited, H2 2016 23

Neisseria meningitidis Infections – Pipeline by China National Pharmaceutical Group Corporation, H2 2016 24

Neisseria meningitidis Infections – Pipeline by GlaxoSmithKline Plc, H2 2016 25

Neisseria meningitidis Infections – Pipeline by ImmunoBiology Limited, H2 2016 26

Neisseria meningitidis Infections – Pipeline by JN-International Medical Corporation, H2 2016 27

Neisseria meningitidis Infections – Pipeline by MGB Biopharma Limited, H2 2016 28

Neisseria meningitidis Infections – Pipeline by Panacea Biotec Limited, H2 2016 29

Neisseria meningitidis Infections – Pipeline by Pfizer Inc., H2 2016 30

Neisseria meningitidis Infections – Pipeline by Sanofi Pasteur SA, H2 2016 31

Neisseria meningitidis Infections – Pipeline by Serum Institute of India Limited, H2 2016 32

Neisseria meningitidis Infections – Pipeline by Wellstat Vaccines, LLC, H2 2016 33

Assessment by Monotherapy Products, H2 2016 34

Assessment by Combination Products, H2 2016 35

Number of Products by Stage and Target, H2 2016 37

Number of Products by Stage and Mechanism of Action, H2 2016 38

Number of Products by Stage and Route of Administration, H2 2016 40

Number of Products by Stage and Molecule Type, H2 2016 42

Neisseria meningitidis Infections – Dormant Projects, H2 2016 88

Neisseria meningitidis Infections – Dormant Projects (Contd..1), H2 2016 89

Neisseria meningitidis Infections – Discontinued Products, H2 2016 90

List of Figures

List of Figures

Number of Products under Development for Neisseria meningitidis Infections, H2 2016 11

Number of Products under Development for Neisseria meningitidis Infections – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 34

Assessment by Combination Products, H2 2016 35

Number of Products by Targets, H2 2016 36

Number of Products by Stage and Targets, H2 2016 36

Number of Products by Routes of Administration, H2 2016 39

Number of Products by Stage and Routes of Administration, H2 2016 39

Number of Products by Molecule Types, H2 2016 41

Number of Products by Stage and Molecule Types, H2 2016 41

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports